Periprocedural coagulability in patients undergoing ablation of atrial fibrillation: Lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 4, 2014, Pages 393-399

  Sairaku, Akinori ^a,b   Yoshida, Yukihiko ^a   Hirayama, Haruo ^a   Nakano, Yukiko ^b   Kihara, Yasuki ^b  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Ablation; Atrial fibrillation; D dimer; INR; Warfarin

Indexed keywords

D DIMER; HEPARIN; WARFARIN; ANTICOAGULANT AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CATHETER ABLATION; CATHETER SHEATH; CONTROLLED STUDY; FEMALE; GROIN HEMATOMA; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS DRAINAGE; PRIORITY JOURNAL; THROMBOEMBOLISM; VASCULAR ACCESS; AGED; ATRIAL FIBRILLATION; BLOOD; CLINICAL TRIAL; FOLLOW UP; METABOLISM;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CATHETER ABLATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; WARFARIN;

EID: 84899931224     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0982-0     Document Type: Article

References (22)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL et al (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 123:e269-e367
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891
4. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ et al (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 9(632-696):e21
5. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L et al (2007) Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 116:2531-2534 (Pubitemid 350179218)
6. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D et al (2010) Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 121:2550-2556
7. Kim JS, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T, Yokokawa M et al (2013) The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol 6:302-309
8. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y et al (2013) A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 36:172-179
9. Genewein U, Haeberli A, Straub PW, Beer JH (1996) Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 92:479-485 (Pubitemid 26042945)
10. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD, Beevers DG (1996) Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 94:425-431 (Pubitemid 26266127)
11. JCS Joint Working Group (2010) Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 74:2479-2500
12. Ouyang F, Bänsch D, Ernst S, Schaumann A, Hachiya H, Chen M, Chun J et al (2004) Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double- Lasso technique in paroxysmal atrial fibrillation. Circulation 110: 2090-2096 (Pubitemid 39372484)
13. White RH, McKittrick T, Hutchinson R, Twitchell J (1995) Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 122:40-42
14. Palareti G, Legnani C (1996) Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet 30:300-313
15. Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, Hasegawa D et al (2007) Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 28:2217-2222 (Pubitemid 47428949)
16. Sadanaga T, Sadanaga M, Ogawa S (2010) Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 55:2225-2231
17. Lee DS, Dorian P, Downar E, Burns M, Yeo EL, Gold WL, Paquette M et al (2001) Thrombogenicity of radiofrequency ablation procedures: what factors influence thrombin generation? Europace 3:195-200 (Pubitemid 32624496)
18. Bulava A, Slavík L, Fiala M, Heinc P, Skvarilova M, Lukl J, Krcová V et al (2004) Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol 10:271-279 (Pubitemid 39024220)
19. Wada H, Ikuma H, Mori Y, Shimura M, Hiyoyama K, Nakasaki T, Onoda K et al (2000) Increased hemostatic molecular markers in patients undergoing anticoagulant therapy. Semin Thromb Hemost 26:113-118 (Pubitemid 30238028)
20. Sairaku A, Nakano Y, Oda N, Makita Y, Kajihara K, Tokuyama T, Kihara Y (2011) Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation. J Interv Card Electrophysiol 31: 157-164
21. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS et al (2013) Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 368: 2084-2093
22. Hoke M, Koppensteiner R, Schillinger M, Haumer M, Minar E, Wiesbauer F, Huber CD et al (2010) D-dimer testing in the diagnosis of transfemoral pseudoaneurysm after percutaneous transluminal procedures. J Vasc Surg 52:383-387